Results 141 to 150 of about 11,461 (257)
Tattooing in Hidradenitis Suppurativa [PDF]
Philippe Guillem, Nicolas Kluger
openaire +2 more sources
Hidradenitis suppurativa (HS), is a chronic disease with inflammatory changes in areas with apocrine glands. The disease presents as inflammatory nodules, abscesses, draining tunnels and scarring.
Pasternack, R. (Rafael) +1 more
core
Hidradenitis suppurativa (HS) is often diagnosed late, complicating management. In this nationwide Danish study including 10,196 patients with dermatologist‐verified HS, we examined treatment patterns before and after referral to specialised hospital care.
Nana A. L. Rosenø +8 more
wiley +1 more source
Assessing the Effect of Adalimumab in Granuloma Annulare: A Case Series and Literature Review
ABSTRACT Granuloma annulare (GA) is a benign granulomatous skin disorder for which standardized treatment guidelines are lacking due to limited evidence. Adalimumab, a TNF‐α inhibitor, shows promise as a therapeutic option due to its potential to disrupt GA granulomas.
Adriana Caixinha Valorenzos +2 more
wiley +1 more source
Interventions for hidradenitis suppurativa
Hidradenitis suppurativa (HS) is a chronic inflammatory dermatosis that presents with inflammatory nodules, abscesses, sinus tracts, and scarring with predilection for intertriginous regions.
Robert Boyle +10 more
core
ABSTRACT Background Hidradenitis suppurativa (HS) is a chronic, recurrent inflammatory skin disease characterised by painful nodules, abscesses, and draining and non‐draining tunnels. Currently, there are two biologics approved in Canada for the treatment of moderate‐to‐severe HS, adalimumab (anti‐TNF) and secukinumab (anti‐IL‐17A).
Irina Turchin +4 more
wiley +1 more source
New Biologic and Small Molecule Therapies for Hidradenitis Suppurativa
ABSTRACT Hidradenitis suppurativa (HS) is an inflammatory skin disease that has historically been underdiagnosed and, until recently, under‐researched. Furthermore, the pathophysiology of HS is complex, and not fully understood. Just three biologic medications—adalimumab (anti‐TNF‐α), secukinumab (anti‐IL17A) and bimekizumab (anti‐IL17A/F) are licensed
Emily Pender +2 more
wiley +1 more source
Ethnicity and Hidradenitis Suppurativa [PDF]
Reeder, Virginia J. +2 more
openaire +2 more sources
Clinical Breakthrough in Targeted Protein Degradation: Reflections on the Approval of ARV‐471
Cancer Innovation, Volume 5, Issue 3, June 2026.
Yu Rao
wiley +1 more source
Overall Cumulative Burden of Hidradenitis Suppurativa: An In‐Depth Qualitative Examination
This qualitative study examined the cumulative burden of Hidradenitis Suppurativa (HS) through in‐depth cross‐sectional interviews with 40 patients. The thematic analysis revealed five major concepts: challenging choices, prevalent negative emotions (fear, anxiety, depression), companionship (social support/isolation), life being ‘on hold’ due to ...
Burhan A. Buttar +13 more
wiley +1 more source

